Which of the following statements about the investigator's brochure is correct?

The Investigator's Brochure (IB) is a comprehensive document that compiles the clinical and nonclinical data on an investigational product. Its primary purpose is to provide investigators and other trial staff with the information necessary to understand the rationale for the trial and to ensure the safe management of study subjects. This includes a summary of pharmacology, toxicology, pharmacokinetics, and metabolic data from nonclinical (animal) studies, as well as all available data from prior clinical (human) studies, including known risks and adverse effects. This information is critical for the investigator's risk/benefit assessment.

A. This statement describes the study protocol, which contains the detailed objectives, design, methodology, and procedures for conducting the trial.

C. Financial disclosure information is a separate regulatory requirement to document any potential conflicts of interest and is not included in the Investigator's Brochure.

D. This describes the purpose of "Essential Documents" as a whole, which are collected to permit evaluation of the trial's conduct and data quality. The IB is one of these documents, but this is not its specific function.

1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Guideline for Good Clinical Practice E6(R2). November 16, 2016.

Section 7.1, Introduction: "The Investigator's Brochure (IB) is a compilation of the clinical and nonclinical data on the investigational product(s) that are relevant to the study of the product(s) in human subjects."

Section 7.3.4, Nonclinical Studies: Specifies that summaries of nonclinical pharmacology, toxicology, and pharmacokinetic studies should be included.

Section 7.3.5, Effects in Humans: States that a discussion of the known effects in humans, including pharmacology, pharmacokinetics, safety, and efficacy, should be provided.

2. U.S. Food and Drug Administration (FDA). Code of Federal Regulations Title 21, Part 312.23(a)(5) (IND Content and Format).

This section mandates that an Investigational New Drug (IND) application must contain an Investigator's Brochure, describing it as containing "a brief description of the drug substance... a summary of the pharmacological and toxicological effects of the drug in animals and, to the extent known, in humans."

3. Johns Hopkins University. Investigator's Brochure (IB) Guidance. Institute for Clinical and Translational Research.

"The Investigator’s Brochure (IB) is a comprehensive document summarizing the body of information about an investigational product (“IP” or “study drug”). The IB contains preclinical (animal) and clinical (human) data that are relevant to the study of the product in human subjects." This university guidance directly reflects the official regulatory definitions.